Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11254726 LILRB1-based chimeric antigen receptor

Patent 11254726 was granted and assigned to A2 Biotherapeutics, Inc on February, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

A2 Biotherapeutics, Inc

Current Assignee

A2 Biotherapeutics, Inc

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Kiran Deshmukh0

Mark E. Daris0

Carl Alexander Kamb0

Agnes E. Hamburger0

Breanna Diandreth0

Date of Patent

February 22, 2022

0

Patent Application Number

172306370

Date Filed

April 14, 2021

0

Patent Citations

US Patent 10172886 Cell

0

US Patent 10040846 Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

US Patent 10172885 Cell

Patent Citations Received

US Patent 11602544 Compositions and methods for treating EGFR positive cancers

US Patent 11602543 Compositions and methods for treating mesothelin positive cancers

US Patent 11433100 Compositions and methods for treating ceacam positive cancers

0

Patent Primary Examiner

0

Patent abstract

Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11254726 LILRB1-based chimeric antigen receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool